Home/Filings/4/0000899243-19-001869
4//SEC Filing

Oxtoby Andrew 4

Accession 0000899243-19-001869

CIK 0001631650other

Filed

Jan 23, 7:00 PM ET

Accepted

Jan 24, 4:06 PM ET

Size

7.8 KB

Accession

0000899243-19-001869

Insider Transaction Report

Form 4
Period: 2019-01-22
Oxtoby Andrew
Chief Commercial Officer
Transactions
  • Award

    Common Stock, $0.0001 par value

    2019-01-22+12,00012,000 total
  • Award

    Stock Option (right to buy)

    2019-01-22+150,000150,000 total
    Exercise: $21.94Exp: 2029-01-22Common Stock (150,000 underlying)
Footnotes (2)
  • [F1]These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from January 22, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
  • [F2]The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 22, 2020 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.

Issuer

Aimmune Therapeutics, Inc.

CIK 0001631650

Entity typeother

Related Parties

1
  • filerCIK 0001765473

Filing Metadata

Form type
4
Filed
Jan 23, 7:00 PM ET
Accepted
Jan 24, 4:06 PM ET
Size
7.8 KB